Lipids and diabetic nephropathy

Current Diabetes Reports

Volumn 6, Issue 6, 2006, Pages 455-462

  Rosario, Rey F ^b   Prabhakar, Sharma ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; APOLIPOPROTEIN E; ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICERITROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

APHERESIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DYSLIPIDEMIA; GENETIC POLYMORPHISM; GLYCEMIC CONTROL; GOUT; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; KIDNEY INJURY; LIFESTYLE; LIPID BLOOD LEVEL; LIPOLYSIS; LOW FAT DIET; MYOSITIS; NONHUMAN; PATHOGENESIS; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; RENAL PROTECTION; REVIEW; RISK FACTOR; SIDE EFFECT;

ANGIOTENSIN II; ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS E; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DYSLIPIDEMIAS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POLYMORPHISM, GENETIC; SAFETY;

EID: 33845417585     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0079-7     Document Type: Review

References (58)

1. Ayodele OE, Alebiosu CO, Salako BL: Diabetic nephropathy - a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 2004, 96:1445-1454.
2. Parving HH, Mauer M, Ritz E: Diabetic nephropathy. In Brenner & Rector's The Kidney, edn 7. Edited by Brenner BM. Philadelphia: WB Saunders; 2004:1777-1818.
3. Moorhead JF, El Nahas M, Chan MK, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982, 1:1309-1311.
4. Krolewski AS, Warram JHG, Christlies AR: Hypercholesterolemia-A determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994, 45:S125-S131.
5. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type 2: effect of ACE inhibitors. Kidney Int 1995, 47:907-910.
6. Gall MA, Hougaard P, Barch-Johnsen K, et al.: Risk factors for development of incipient and overt diabetic nephropathy in patients with noninsulin-dependent diabetes mellitus: prospective observational study. BMJ 1997, 314:783-788.
7. Klein R, Klein BEK, Moss SE, et al.: The 10-year incidence of renal insufficiency in people with type-1 diabetes. Diabetes Care 1999, 22:743-751.
8. Bonnet F, Cooper ME: Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab 2000, 26:254-264.
9. Hirano T: Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl 1999, 71:S22-S24.
10. Chen HC, Guh JY, Chang JM, et al.: Role of lipid control in diabetic nephropathy. Kidney Int 2005, 67:S60-S62.
11. Trovati M, Cavalot F: Optimization of hypolipidemic and antiplatelet treatment in the diabetic patient with renal disease. J Am Soc Nephrol 2004, 15:S12-S20.
12. Kahri J, Groop PH, Elliott T, et al.: Plasma cholesteryl ester transfer protein and its relationship to plasma lipoproteins and apolipoprotein A-I containing lipoproteins in IDDM patients with microalbuminuria and clinical nephropathy. Diabetes Care 1994, 17:412-419.
13. Groop PH, Elliott T, Ekstrand A, et al.: Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 1996, 45:974-979.
14. Jensen T, Stender S, Deckert T: Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 1988, 31:142-145.
15. Jerums G, Allen TJ, Tsalamandris C, et al.: Relationship of progressively increasing albuminuria to apoprotein[a] and blood pressure in type 2 (non insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia 1993, 36:1037-1044.
16. Kasiske BL, O'Donnell MP, Schmitz PG, et al.: The renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990, 37:880-891.
17. Misra Luthra K, Misra A, Srivastava LM: Lipoprotein (a): biology and role in atherosclerotic vascular disease. Curr Sci 1999, 76:1553-1560.
18. Grone HJ, Hohbach J, Grone EF: Modulation of glomerulosclerosis and interstitial fibrosis by native and modified lipoprotein. Kidney Int Suppl 1996, 49:S18-S22.
19. Chander PN, Gealekman O, Brodsky SV, et al.: Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 2004, 15:2391-2403.
20. Takemura T, Yoshioka K, Aya N, et al.: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993, 43:918-927.
21. Guijarro C, Kasiske BL, Kim Y, et al.: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis, 1995, 26:152-161.
22. Pesek-Diamond I, Ding G, Frye J, Diamond JR: Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 1992, 263:F776-F783.
23. Cooper ME, Jandeleit-Dahm KAM: Lipids and diabetic renal disease. Curr Diab Rep 2005, 5:445-448.
24. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2-15.
25. Schlondorff D: Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 1993, 22:72-82.
26. Krane V, Wanner C: At which stage of chronic kidney disease should dyslipidemia be treated? Nat Clin Pract Nephrol 2006, 2:176-177.
27. Keilani T, Schlueter W, Batlle D: Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium. J Clin Pharmacol 1995, 35:87-97.
28. Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993, 22:196-201.
29. Wilson WF, Myers RH, Larson MG, et al.: Apolipoprotein E alleles, dyslipidemia and coronary artery disease: the Framingham offspring study. JAMA 1994, 272:1666-1671.
30. Chowdhury TA, Dyer PH, Kumar S, et al.: Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with NIDDM. Diabetes 1998, 47:278-280.
31. Werle E, Fiehn W, Hasslacher C: Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care 1998, 21:994-998.
32. Onuma T, Laffel LM, Angelico MC, Krolewski AS: Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol 1996, 7:1075-1078.
33. Hadjadj S, Gallois Y, Bouhanick B, et al.: Lack of contribution of lipid gene polymorphisms to IDDM nephropathy: the GENEDIAB Study [abstract]. Diabetologia 1998, 41(suppl 1):A293.
34. Eto M, Saito M, Okada M, et al.: Apolipoprotein e genetic polymorphism, remnant lipoproteins, and nephrology in type 2 diabetic patients. Am J Kidney Dis 2002, 40:243-251.
35. Kimura H, Suzuki Y, Gejyo F, et al.: Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 1998, 31:666-673.
36. Boizel R, Benhamou PY, Corticelli P, et al.: Apo E polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant 1998, 13:72-75.
37. Forbes JM, Cooper ME, Oldfield MD, Thomas MC: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S254-S258.
38. Lassila M, Seah KK, Allen TJ, et al.: Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004, 15:2125-2138.
39. McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002, 87:1457-1458.
40. Athyros VG, Papageorgiou AA, Elisaf M, Mikhalidis DP: Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003, 19:615-617.
41. Inman SR, Stowe NT, Cressman MD, et al.: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 1999, 317:215-221.
42. Kim SI, Han DC, Lee HB: Lovastatin inhibits transforming growth factor-beta 1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000, 11:80-87.
43. Jandeleit-Dahm K, Cao Z, Cox AJ, et al.: Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl 1999, 56:S31-S36.
44. Lee SK, Jin SY, Han DC, et al.: Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 1993, 8:1338-1343.
45. Park YS, Guijarro C, Kim Y, et al.: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998, 31:190-194.
46. Fried LF, Orchard TJ, Kasiske BL: The effect of lipid reduction on renal disease progression. A meta-analysis. Kidney Int 2001, 59:260-269.
47. Lam KSL, Cheng IKP, Janus ED, et al.: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995, 38:604-609.
48. Tonolo G, Calvia P, Ciccarese M, et al.: Reduction of albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994, 45:S145-S149.
49. Smulders YM, van Eeden AE, Stehouwer CD, et al.: Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997, 27:997-1002.
50. Harris KPG, Wheeler DC, Chong CC: A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. The Atorvastatin in CAPD Study investigators. Kidney Int 2002, 61:1469-1474.
51. PDR Drug Interactions. In The PDR Electronic Library Version. Montvale, NJ: Thomson PDR; 2004:6.1.301A-304A.
52. Weiner DE, Sarnak MJ: Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004, 19:1045-1052.
53. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group [no authors listed]. Diabetes Care 2001, 24:1335-1341.
54. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
55. Owada A, Suda, S, Hata T: Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am J Med 2003, 1i4:347-353.
56. Stewart KJ: Exercise training and the cardiovascular consequences of type-2 diabetes and hypertension. Plausible mechanisms for improving cardiovascular health. JAMA 2002, 288:1622-1631.
57. Nakamura T, Kawagoe Y, Ogawa H, et al.: Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am J Kidney Dis 2005, 45:48-53.
58. Haffner SM; American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care 2003, 26(suppl 1):S83-S86.